NVIDIA unveils new AI programs for drug discovery, design

Today’s Big News

Mar 20, 2024

#FierceMadness is back: Get voting in the 2024 drug name tournament 


Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug 


Nvidia unveils generative AI programs for drug molecule design, protein predictions 


#FierceMadness: The best biotech name tournament 


With exec appointments and new pharma unit, Bayer's overhaul takes shape

 

Featured

#FierceMadness is back: Get voting in the 2024 drug name tournament

It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names.
 

Top Stories

Orchard sets new gene therapy price tag at $4.25M—the steepest of any drug

After scoring an FDA nod Monday for the first gene therapy to treat the rare genetic disease metachromatic leukodystrophy in the U.S., Kyowa Kirin and its subsidiary Orchard Therapeutics have broken new boundaries in pricing, too.

Nvidia unveils generative AI programs for drug molecule design, protein predictions

A little more than a year after announcing plans to move its molecule design programs into the field of generative AI, Nvidia is setting up shop.

#FierceMadness: The Best Biotech Name Tournament

What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket.

With exec appointments and new pharma unit, Bayer's overhaul takes shape

Early this month at an investor event, Bayer CEO Bill Anderson declared that employees “are ready for change." On Wednesday, Anderson answered the call with changes to the company’s leadership. In the pharma sector, Bayer revealed a new Global Commercialization unit, which will be led by Christine Roth. The company also tabbed Sebastian Guth as its chief operating officer.

Third Rock, Novo Holdings-backed Clasp Tx hooks $150M series A for next-gen cancer treatments

A new immuno-oncology biotech has emerged, clasping $150 million that will go toward developing next-gen T cell engagers (TCEs) targeting a range of hard-to-treat tumors.

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.

Ad astra: Regeneron launches stargazing-themed campaign for high-dose Eylea

As its high-dose Eylea continues to duke it out with Roche’s Vabysmo to be the go-to treatment for age-related macular degeneration and diabetic macular edema, Regeneron is hitching its wagon to several constellations’ worth of stars.

Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen

Acelyrin's subcutaneous thyroid eye disease treatment posted proof-of-concept data that were similar to Amgen's Tepezza. The readout is the latest in a wave of data that's fortified the biotech's 2024 comeback effort.

After Opdivo flop in liver cancer, Bristol Myers finds Yervoy combo could save lives

Bristol Myers Squibb is gunning for newly diagnosed unresectable liver cancer—again—after its Opdivo monotherapy setback five years ago and a subsequent market withdrawal.

Ted Danson cheers progress on psoriasis, teaming with BMS to help patients reach a good place

Ted Danson has teamed up with Bristol Myers Squibb to show how plaque psoriasis patients can get to a good place. The actor, who developed psoriasis aged 25, is fronting a new campaign to show how BMS’ Sotyktu can help alleviate physical, mental and social burdens linked to the skin condition.

Lonza strikes $1.2B deal to buy mammoth Roche plant amid CDMO industry upheaval

In a bid to corner contracts on next-generation medicines, production juggernaut Lonza is picking up one of the world’s biggest biologics manufacturing facilities from its Swiss compatriot Roche.

Johnson Matthey sells off medtech metal manufacturing unit to Montagu in $700M private equity deal

After the deal for MDC closes, it is set to operate as a standalone company led by its current management, according to Montagu.

Qiagen teams with International Panel Physicians Association for tuberculosis screening awareness

Medical testing company Qiagen is joining forces with the International Panel Physicians Association (IPPA) to boost awareness around tuberculosis testing.
 
Fierce podcasts

Don’t miss an episode

'The Top Line': Inclusivity in psoriasis trials with Takeda

In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials.
 

Resources

Whitepaper

Pediatric Clinical Trials: Considerations for Enrollment and Retention

Explore the nuanced approaches necessary for successful pediatric drug development.
Whitepaper

CNS Market Outlook, 2024

This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment.

 

Industry Events

 

Upcoming Fierce Events

18-20
Mar
Savannah, GA
6-8
May
Jersey City, NJ
13-15
May
Newport Beach, CA
14-15
May
Newport Beach, CA
21-23
May
Free Virtual Event

View all events